Industry News

Tonix Pharmaceuticals Holding Corp., which is developing a next-generation treatment for posttraumatic stress disorder, announced today that it will present at the Rodman& Renshaw 18 th Annual Global Investment Conference being held September 11-13, 2016 in New York, NY.. Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of Tonix’ s PTSD clinical program. Tonix recently announced a..."/>
Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Endo International PLC, Teva Pharmaceutical Industries Ltd, Ionis Pharmaceuticals Inc., and Catalent Inc.. Over the past five years, the MSCI All Country Healthcare index has outperformed the global stock market by over 60%."/>
Research Reports on Healthcare Equities -- Endo, Teva Pharma Industries, Ionis Pharma, and Catalent
Stemline Therapeutics, Inc. announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will present at the Rodman& Renshaw 18 th Annual Global Investment conference on Monday, September 12, 2016 at 3:50 PM ET. The conference will be held at the Lotte New York Palace Hotel in New York, NY. A live webcast of the presentation can be viewed on the company’ s website at www.stemline.com."/>
Stemline Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
OpGen, Inc. an informatics and genomic analysis company, announces that Evan Jones, the Company’ s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman& Renshaw 18th Annual Global Investment Conference. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.."/>
OpGen to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Rodman& Renshaw 18th Annual Global Investment Conference in New York City on Tuesday, September 13, 2016, at 3:50 p.m. ET.."/>
Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Seth H.Z. Fischer to its Board of Directors.. “Seth brings over 30 years of pharmaceutical operations and commercialization experience,” stated Christopher M. Cashman, chairman and chief executive officer of Marinus Pharmaceuticals.“ Seth has..."/>
Marinus Appoints Seth H.Z. Fischer to its Board of Directors
Halyard Health, Inc. today announced that Robert Abernathy, chairman and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt hotel in New York on Tuesday, Sept. 13 at approximately 10 a.m., ET. A webcast of the conference presentation will be available on the Investors section of the Halyard Health website and will be archived on that site. About Halyard Health: Halyard Health is a medical..."/>
Halyard Health, Inc. to Present at Morgan Stanley Global Healthcare Conference
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first patient in the multiple ascending dose portion of its ongoing Phase 1/ 2 study of ARC-521, the company’ s second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus infection. To date 24 healthy volunteers have been treated in the study, and the drug safety committee approved initiation of the MAD after a planned review of safety data from cohort 3 of the..."/>
Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521
Immune Pharmaceuticals Inc., a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of the Company's common stock at a fixed price of $0.50 per share, for gross proceeds of $2,000,000. There are no warrants, no restrictive covenants,..."/>
Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share
MEI Pharma stated on Tuesday that it recorded a net loss of USD20.9m for its fiscal year ended 30 June 2016.. This marks an improvement in earnings when compared with a higher net loss of USD32.7m for 2015.. Research and development expenses of USD13.4m were recorded for the year ended 30 June 2016, a decline over R&D of USD23.8m for 2015, primarily due to a reduction in clinical trial, production and development costs of Pracinostat."/>
MEI Pharma incurs lower net loss of USD20.9m for fiscal 2016
Aerie Pharmaceuticals revealed on Tuesday that it has submitted its New Drug Application to the US Food and Drug Administration for Rhopressa 0.02% to treat patients with glaucoma or ocular hypertension. The company said Rhopressa is a novel once-daily eye drop designed to lower intraocular pressure in patients with glaucoma or ocular hypertension. This US FDA filing includes the results of the company's first two Phase 3 registration trials for..."/>
Aerie Pharmaceuticals submits NDA to US FDA for Rhopressa 0.02% for treating glaucoma or ocular hypertension
Apricus Biosciences reported on Tuesday the market launch of its novel on-demand topical cream Vitaros for the treatment of erectile dysfunction in Portugal, Ireland and Poland via Recordati. As part of the agreement, Recordati will commercialise the product in Portugal and Ireland as Vitaros and in Poland as Vytaros. Under the terms of a previous agreement, Apricus is eligible to receive up to approximately USD39.7m from Recordati in additional..."/>
Apricus Biosciences unveils Vitaros in Portugal, Ireland and Poland
GHP Specialty Care names Philip Delborn as new CFO
Myriad Genetics, Inc. a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the ability to perform standardized transcriptome profiling based upon a variety of immune stimuli in the August issue of Cell Reports. The study looked at the expression levels of different genes..."/>
Myriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced today that the U.S."/>
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing gene and plasma-based therapies for life- threatening rare genetic diseases, today announced that COO, Jeffrey Davis, will be presenting for the company at The Rodman& Renshaw 18th Annual Global Investment Conference in New York City, September 12 th at 2:35 pm ET. The following are the specific details regarding Abeona Therapeutics..."/>
Abeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Veeva Systems today unveiled the results of the Veeva 2016 Paperless TMF Survey: CRO Report. The global industry survey of trial master file owners shows growing use of electronic trial master file solutions among clinical research organizations as a result of benefits in audit and inspection readiness."/>
Global Life Sciences Survey Reveals Significant Improvements in Inspection Readiness Among CROs
Veeva Systems today unveiled the results of the Veeva 2016 Paperless TMF Survey: CRO Report. The global industry survey of trial master file owners shows growing use of electronic trial master file solutions among clinical research organizations as a result of benefits in audit and inspection readiness."/>
Global Life Sciences Survey Reveals Significant Improvements in Inspection Readiness Among CROs
Aquinox Pharmaceuticals reported on Tuesday the start of dosing under its Phase 3 LEADERSHIP 301 clinical trial of AQX-1125 for the treatment of interstitial cystitis/bladder pain syndrome, with top-line data anticipated in the fourth quarter of 2017.. As part of the LEADERSHIP 301 trial, the company will enroll a minimum of 300 female patients and up to 300 male subjects at clinical research centers in Canada, the US and Europe. According to the..."/>
Aquinox Pharmaceuticals initiates dosing under Phase 3 LEADERSHIP 301 clinical trial of AQX-1125 for IC/BPS
Catalent reported on Tuesday the start of a secondary public offering of 19.0 m shares of its common stock. In the public offering, certain selling stockholders of the company are offering all of the approximately 19.0 m shares of its common stock owned by them. The company said it is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the selling stockholders."/>
Catalent discloses secondary public offering of 19.0m common stock
GHP Specialty Care names Philip Delborn as new CFO
RXi Pharmaceuticals Corporation, a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted with the Arizona BioIndustry Association taking place September 18-21, 2016 in Phoenix, Arizona. The purpose of the Forum is to help family offices, foundations and impact investors..."/>
RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum
Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present company updates at the 23 rd Annual BioCentury NewsMakers in the Biotech Industry Conference and the Rodman& Renshaw 18 th Annual Global Investment Conference. Details for the presentations and webcast..."/>
Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences
Natus Medical Incorporated today announced that Jim Hawkins, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference in New York, NY. Hawkins is scheduled to present on Monday, September 12 th at 5:25 p.m. Eastern Time.. Natus Medical Incorporated also announced that Jonathan Kennedy, Sr."/>
Natus to Present at Morgan Stanley Global Healthcare Conference and 7th Annual Credit Suisse Small & Mid Cap Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology664 Articles
Consumer Discretionary606 Articles
Financials440 Articles
Health Care379 Articles
Industrials377 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.